Natera beats Q2 revenue forecast on record test volumes, raises guidance

Natera reported Q2 2026 revenue of about $753 million, beating Wall Street forecasts by nearly 14%, causing shares to surge 16% in after-hours trading. The company processed approximately 1.044 million tests, a quarterly record, with clinical MRD test volume up 56% year over year. Management raised full-year 2026 revenue guidance to $2.85 billion–$2.91 billion. Gross margin was about 65%. Natera cited record test volumes, improved margins, and regulatory gains. The company reported positive cash flow and expects continued growth, though profitability remains a work in progress as it invests in early cancer detection.